Sit Investment Associates Inc. Sells 2,400 Shares of Thermo Fisher Scientific Inc. (TMO)

Sit Investment Associates Inc. decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 38,282 shares of the medical research company’s stock after selling 2,400 shares during the period. Sit Investment Associates Inc.’s holdings in Thermo Fisher Scientific were worth $7,269,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the company. Amalgamated Bank lifted its stake in shares of Thermo Fisher Scientific by 57.0% during the 2nd quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock worth $7,837,000 after acquiring an additional 16,308 shares during the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of Thermo Fisher Scientific by 2.1% during the 2nd quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock worth $8,327,000 after acquiring an additional 977 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its stake in shares of Thermo Fisher Scientific by 0.9% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after acquiring an additional 5,213 shares during the last quarter. San Francisco Sentry Investment Group CA bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $1,451,000. Finally, Huntington National Bank lifted its stake in shares of Thermo Fisher Scientific by 2.4% during the 3rd quarter. Huntington National Bank now owns 195,348 shares of the medical research company’s stock worth $36,959,000 after acquiring an additional 4,655 shares during the last quarter. Hedge funds and other institutional investors own 86.22% of the company’s stock.

Shares of Thermo Fisher Scientific Inc. (NYSE TMO) opened at $208.66 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. The firm has a market capitalization of $83,230.00, a price-to-earnings ratio of 35.43, a price-to-earnings-growth ratio of 1.65 and a beta of 1.06. Thermo Fisher Scientific Inc. has a 1 year low of $140.00 and a 1 year high of $208.72.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 9.09% and a net margin of 10.44%. Thermo Fisher Scientific’s revenue was up 13.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.03 EPS. equities research analysts predict that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.19%.

TMO has been the subject of a number of research analyst reports. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price target for the company in a research note on Tuesday, October 31st. Leerink Swann reissued an “outperform” rating and set a $200.00 price target (down from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday, December 4th. Deutsche Bank set a $226.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a research note on Thursday, October 26th. Barclays reissued an “overweight” rating and set a $215.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Finally, Goldman Sachs Group initiated coverage on Thermo Fisher Scientific in a research note on Tuesday, September 26th. They set a “buy” rating and a $225.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have issued a buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus target price of $212.21.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the sale, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.49% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.com-unik.info/2018/01/12/sit-investment-associates-inc-sells-2400-shares-of-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit